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Abstract
Background: We aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients
with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME).
Methods: Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively
collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups
according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant
and observation groups. To control for potential confounding factors, we also calculated propensity scores and
performed propensity score-matched analysis for DFS and OS.
Results: Of the 339 evaluated patients, 87 patients (25.7%) did not receive AC. There were no differences in
DFS (hazard ratio [HR], 0.921; 95% confidence interval [CI], 0.562–1.507; P = 0.742) and OS (HR, 0.835; 95% CI,
0.423–1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS
(HR, 1.129; 95% CI, 0.626–2.035; P = 0.688) and OS (HR, 1.200; 95% CI, 0.539–2.669; P = 0.655) did not differ
between the adjuvant and observation groups. Advanced T stage and positive resection margin were
independently associated with inferior DFS and OS on multivariate analysis.
Conclusions: AC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative
CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer
should be evaluated in prospective randomized trials with a larger sample size.
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Background
Total mesorectal excision (TME) has substantially con-
tributed to improvement in loco-regional recurrence
rates and survival for patients with rectal cancer [1]. In
addition, benefits in local disease control, toxicity, and
sphincter preservation have been achieved by
preoperative chemoradiation therapy (CRT), which is
the currently standard management for locally advanced
rectal cancer (LARC) [2]. Therefore, the focus on im-
proving outcomes has changed from lowering the local
recurrence rate to reducing distant recurrence, which
still occurs in approximately one-third of patients
treated surgically with curative intent [3]. In colon can-
cer, adjuvant single agent 5-fluorouracil (5-FU) chemo-
therapy has led to an increase in overall survival (OS), of
approximately 10% for patients with American Joint
Committee on Cancer (AJCC) stage III disease and a
further 5% by adding oxaliplatin [4–7]. Based on this
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background, many researchers have tried to extrapolate
the benefits of adjuvant chemotherapy (AC) for colon
cancer to the treatment of rectal cancer. Even if a surgi-
cal specimen obtained from radical resection reveals a
complete response without any viable tumor cells, the
patient is expected to complete 4–6 months of AC based
on their clinical stage, which was estimated before pre-
operative treatment [8, 9].
However, the efficacy of AC in patients with LARC
after preoperative CRT and TME has not been docu-
mented to the same extent, and the clinical benefit re-
mains controversial [10]. In this context, international
and national treatment guidelines differ in their recom-
mendations regarding to AC in LARC [11, 12]. The ini-
tial results of the EORTC 22921 trial indicated that only
patients with a good prognosis (ypT0–2) benefited from
AC [13]. However, the final results indicated that
adjuvant 5-FU-based chemotherapy after preoperative
radiotherapy with or without chemotherapy did not
improve disease-free survival (DFS) and OS in all
patients, including patients with a good prognosis
(ypT0–2) [14]. In contrast, patients with a high risk for
recurrence (yp stage III) benefited from adding oxalipla-
tin to 5-FU as AC after preoperative 5-FU-based CRT
and TME [15]. With these heterogeneous results about
the role of AC, we aimed to investigate the value of AC
with fluoropyrimidine mono-therapy after preoperative
CRT and TME in ypT0-3N0 patients, who are consid-
ered to have a good prognosis.
Methods
Patients and pretreatment evaluation
Patients who were diagnosed with LARC, were treated
with preoperative CRT and TME, and had ypT0-3N0M0
as the final pathologic diagnosis at Yonsei Cancer Center
between January 2001 and December 2013 were in-
cluded. Patients who underwent trans-anal excision and
received AC with oxaliplatin were excluded.
Pathologic diagnosis by biopsy was performed for all
patients before treatment. To determine the clinical
stage, the pretreatment evaluation involved a physical
examination including a digital rectal examination; carci-
noembryonic antigen (CEA); abdomino-pelvic computed
tomography (CT); chest CT; rectal magnetic resonance
imaging; and positron emission tomography (PET)-CT,
when there was a suspicion of distant metastasis.
Clinical and pathologic staging were determined accord-
ing to the AJCC TNM staging system, 7th edition [16].
Treatment and follow-up
Preoperative radiation therapy involved a total of 45–50.4
Gray radiation delivered in 25–28 fractions to the tumor
and drained lymph node. Preoperative chemotherapy
with concurrent radiotherapy included 5-FU
administered as a 400-mg/m2 bolus and leucovorin ad-
ministered as a 20-mg/m2 bolus during the first and
last weeks of radiotherapy or 850-mg/m2 capecitabine
twice a day during the entire period of radiotherapy.
Surgical resection with TME was performed 4–8 weeks
after completion of the CRT.
AC consisted of 5-FU administered as a 400-mg/m2
bolus and leucovorin administered as a 20-mg/m2 bolus
on days 1–5 every 28 days for 4 cycles or 1250-mg/m2
capecitabine twice a day on days 1–14 every 21 days for
5 cycles. The chemotherapeutic agents were the same as
those used in the preoperative CRT.
Patients were followed at 3-month intervals during the
first 2 years after surgery, at 6-month intervals during
the next 3 years, and annually thereafter. At each visit
during the regular follow-ups, a serum CEA assay was
performed. Abdomino-pelvic CT was performed at 6-
month intervals, chest CT was performed at 12-month
intervals, and both were performed annually after 5 years.
If recurrence was suspected, the follow-up examinations
included a clinical evaluation, physical examination,
serum CEA assay, chest CT, abdomino-pelvic CT, colon-
oscopy, and PET, as appropriate. Recurrence was deter-
mined using clinical and radiological examinations or
histological assessment.
Statistical analysis
To evaluate the benefit of AC for patients with LARC
treated with preoperative CRT and TME, we compared
survival between the patients with AC (adjuvant group)
and those without AC (observation group). To reduce
the effect of treatment-selection bias and simulate the
effects of randomization, propensity score matching was
used. Propensity scores were estimated using a logistic
regression model based on age, sex, tumor location,
histologic differentiation, pretreatment CEA level, surgi-
cal procedure, pathologic stage, number of retrieved
lymph nodes, lymphovascular or perineural invasion,
and margin involvement. One-to-one matching without
replacement was performed using a 0.2 caliper width,
and the resulting score-matched pairs were used in sub-
sequent analyses, as indicated.
The statistical significance of differences was
assessed using the Chi-square test for categorical vari-
ables and Wilcoxon rank sum test for continuous vari-
ables unless specifically mentioned. OS was defined as
the time from the date of surgery to the date of death
from any cause. DFS was defined as the time from the
date of surgery to the detection of recurrent disease or
death, whichever occurred first. Survival curves were
generated using the Kaplan-Meier method, and sur-
vival was compared using Cox regression analysis. To
identify the subpopulations that benefited from AC,
subgroup analysis was performed by stratifying
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patients according to patient demographics and tumor
characteristics in the entire sample as well as the pro-
pensity score-matched cohort. All analyses were con-
ducted with the statistical program R (R Foundation
for Statistical Computing, Vienna, Austria). All P-
values are two-sided, and P < 0.05 was used to denote
statistical significance.
Results
Patient characteristics
Of the 365 patients with LARC (radiological T3–4 or
N+) who underwent neoadjuvant CRT with 5-FU or
capecitabine followed by TME, 5 patients who under-
went a trans-anal excision and 21 patients who
sequentially received AC with oxaliplatin were
excluded (Fig. 1). Therefore, the analyses included 339
patients with ypT0-3N0 primary adenocarcinoma of
the rectum.
The baseline characteristics of all patients are pre-
sented in Table 1. The median number of harvested
lymph nodes was 12 (interquartile range [IQR], 9–17),
and total pathologic complete remission (ypT0N0) was
achieved in 90 patients (26.5%). Of the 399 patients, 87
patients (25.7%) did not receive AC. Compared with
patients who did not receive AC, patients who received
AC were younger, had a more advanced pathologic
stage, and experienced a poor response to preoperative
CRT. Other clinicopathologic characteristics were
similar between the adjuvant and observation groups.
Oncologic outcomes
The mean follow-up duration was 70.7 months (95%
confidence interval, 65.9–75.5 months), and the dur-
ation was similar between the two groups (P = 0.650).
Local recurrence and systemic recurrence occurred in
23 patients (6.8%) and 57 patients (16.8%), respectively.
The lung was the most common site of distant metas-
tasis (37 patients), followed by the liver (16 patients)
and distant lymph nodes (7 patients). A total of 40 pa-
tients died, and 28 deaths occurred due to cancer pro-
gression. No treatment-related mortality was reported.
In the multivariate Cox regression analysis, old age
(>70 years old), abdomino-perineal resection, ad-
vanced pathologic stage (ypT stage), lymphovascular
or perineural invasion, and a positive resection margin
were associated with inferior DFS. In addition, patients
who were older, had an advanced pathologic stage, and
had a positive resection margin showed poor OS in
the multivariate analysis (Table 2). However, there
were no significant differences in DFS and OS based
on AC (Fig. 2). The 5-year DFS were 78.0% in the
observation group and 76.8% in the adjuvant group
(hazard ratio [HR], 0.921; 95% confidence interval
[CI], 0.562–1.507; P = 0.742). AC did not confer a
benefit in terms of both local recurrence (HR, 1.583; 95%
CI, 0.538–4.652; P = 0.404), and systemic recurrence (HR,
1.070; 95% CI, 0.585–1.956; P = 0.825). The 5-year OS
were 91.6% in the observation group and 88.1% in the ad-
juvant group (HR, 0.835; 95% CI, 0.423–1.648; P = 0.603).
Propensity score-matched analysis
We conducted the propensity score-matched analysis
because the patients treated with AC were younger,
had a more advanced pathologic stage, and experi-
enced a poor response to preoperative CRT and these
parameters were independent poor prognostic factors
in the Cox regression analysis. The propensity score
matching resulted in 87 matched pairs, for a total of
174 patients. The patient characteristics were nearly
balanced between the two groups (Table 1). In the pro-
pensity score-matched cohort, there were also no signifi-
cant differences in DFS and OS based on AC
(Fig. 3). The 5-year DFS were 78.0% in the observa-
tion group and 73.7% in the adjuvant group (HR,
1.129; 95% CI, 0.626–2.035; P = 0.688). In addition,
both local recurrence (HR, 2.206; 95% CI, 0.679–
Fig. 1 Flowchart of the study population
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7.165; P = 0.188) and systemic recurrence (HR, 1.089;
95% CI, 0.526–2.258; P = 0.818) did not differ
between the two groups. The 5-year OS were 91.6%
in the observation group and 83.8% in the adjuvant
group (HR, 1.200; 95% CI, 0.539–2.669; P = 0.655).
In the propensity score-matched cohort, advanced
pathologic stage and positive resection margin were
associated with both inferior DFS and OS (Table 3).
Table 1 Baseline characteristics of patients with ypT0-3N0 rectal cancer
Before matching After matching
Overall n = 339 (%) No AC n = 87 (%) AC n = 252 (%) p-value No AC n = 87 (%) AC n = 87 (%) p-value
Median age (range), years 59.6 (27.2–85.7) 65.9 (36.0–85.7) 58.3 (27.2–84.6) <0.001 65.9 (36.0–85.7) 63.7 (39.1–84.6) 0.251
Sex 0.752 0.602
Male 246 (72.6) 62 (71.3) 184 (73.0) 62 (71.3) 59 (67.8)
Female 93 (27.4) 25 (28.7) 68 (27.0) 25 (28.7) 28 (32.2)
Distance from AV (cm) 0.342
≥ 10.0 35 (10.3) 8 (9.2) 27 (10.7) 8 (9.2) 9 (10.3)
5.0–9.9 140 (41.3) 33 (37.9) 107 (42.5) 33 (37.9) 40 (46.0)
< 5.0 164 (48.4) 46 (52.9) 118 (46.8) 46 (52.9) 38 (43.7)
Differentiation 0.176 0.300
Well 70 (20.6) 17 (19.5) 53 (21.0) 17 (19.5) 20 (23.0)
Moderate 248 (73.2) 61 (70.1) 187 (74.2) 61 (70.1) 62 (71.3)
Poor, mucinous 21 (6.2) 9 (10.3) 12 (4.8) 9 (10.3) 5 (5.7)
Pretreatment CEA (ng/mL) 0.621 0.413
< 5 214 (63.1) 53 (60.9) 161 (63.9) 53 (60.9) 58 (66.7)
≥ 5 125 (36.9) 34 (39.1) 91 (36.1) 34 (39.1) 29 (33.3)
Surgical procedure 0.573 0.350
LAR 298 (87.9) 75 (86.2) 232 (88.5) 75 (86.2) 79 (90.8)
APR 41 (12.1) 12 (13.8) 29 (11.5) 12 (13.8) 8 (9.2)
Stage <0.001 0.383
ypT0 90 (26.5) 40 (46.0) 50 (19.8) 40 (46.0) 37 (42.5)
ypT1 19 (5.6) 6 (6.9) 13 (5.2) 6 (6.9) 4 (4.6)
ypT2 96 (28.3) 25 (28.7) 71 (28.2) 25 (28.7) 26 (29.9)
ypT3 134 (39.5) 16 (18.4) 118 (46.8) 16 (18.4) 20 (23.0)
LN dissected 0.146 0.538
< 12 145 (42.8) 43 (49.4) 102 (40.5) 43 (49.4) 39 (44.8)
≥ 12 194 (57.2) 44 (50.6) 150 (59.5) 44 (50.6) 48 (55.2)
LVI/PNI 0.812 0.657
Negative 278 (82.0) 71 (81.6) 207 (82.1) 71 (81.6) 80 (92.0)
Positive 15 (4.4) 3 (3.4) 12 (4.8) 3 (3.5) 2 (2.3)
NA 46 (13.6) 13 (14.9) 33 (13.1) 13 (14.9) 5 (5.8)
Margin 0.677 1.000
Negative 329 (97.1) 85 (97.7) 244 (96.8) 85 (97.7) 85 (97.7)
Positive 10 (2.9) 2 (2.3) 8 (3.2) 2 (2.3) 2 (2.3)
Mandard regression grade <0.001 0.926
Grade 1 90 (26.5) 40 (46.0) 50 (19.8) 40 (46.0) 37 (42.5)
Grade 2 90 (26.5) 17 (19.5) 73 (29.0) 17 (19.5) 22 (25.3)
Grade 3 78 (23.0) 11 (12.6) 67 (26.6) 11 (12.6) 15 (17.2)
Grade 4 36 (10.6) 6 (6.9) 30 (11.9) 6 (6.9) 8 (9.2)
NA 45 (13.3) 13 (14.9) 32 (12.7) 13 (14.9) 5 (5.8)
AC adjuvant chemotherapy, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection,
LN lymph node, LVI lymphovascular invasion, PNI perineural invasion, NA not assessed
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Table 2 Factors associated with disease-free survival and overall survival in the entire sample of patients with ypT0-3N0 rectal cancer
Disease-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age, years 0.002 0.013 0.001 <0.001
< 70 1 1 1 1
≥ 70 2.091 (1.299–3.366) 1.944 (1.148–3.293) 3.026 (1.584–5.780) 3.606 (1.848–7.038)
Sex 0.226 0.051
Female 1 1
Male 1.393 (0.814–2.384) 2.549 (0.998–6.511)
Distance from AV (cm) 0.122 0.302
≥ 10.0 1 1
5.0–9.9 0.754 (0.340–1.674) 0.683 (0.220–2.122)
< 5.0 1.256 (0.591–2.668) 1.184 (0.407–3.443)
Differentiation 0.646 0.327
Well 1 1
Moderate 1.045 (0.591–1.848) 1.103 (0.480–2.536)
Poor, mucinous 1.493 (0.607–3.677) 2.202 (0.692–7.010)
Pretreatment CEA (ng/mL) 0.005 0.057 0.088
< 5 1 1 1
≥ 5 1.877 (1.207–2.918) 1.628 (0.985–2.692) 1.717 (0.923–3.196)
Surgical procedure 0.001 <0.001 0.008 0.059
LAR 1 1 1 1
APR 2.492 (1.480–4.196) 3.919 (1.996–7.697) 2.538 (1.272–5.064) 2.007 (0.974–4.135)
Stage 0.005 0.047 0.007 0.007
ypT0 1 1 1 1
ypT1 2.234 (0.688–7.256) 1.876 (0.505–6.972) 5.049 (1.018–25.046) 4.853 (0.977–24.109)
ypT2 2.317 (1.066–5.038) 2.661 (1.193–5.936) 1.872 (0.483–7.261) 1.488 (0.379–5.842)
ypT3 3.555 (1.732–7.295) 2.917 (1.354–6.284) 5.340 (1.612–17.684) 4.742 (1.419–15.843)
LN dissected 0.119 0.100
≥ 12 1 1
< 12 1.421 (0.913–2.212) 1.691 (0.904–3.166)
LVI/PNI 0.005 0.023 0.445
Negative 1 1 1
Positive 3.047 (1.391–6.678) 2.606 (1.144–5.938) 1.753 (0.415–7.401)
Margin <0.001 <0.001 <0.001 <0.001
Negative 1 1 1 1
Positive 9.165 (4.653–18.050) 6.348 (2.786–14.467) 10.374 (4.546–23.673) 7.933 (3.351–18.779)
Mandard regression grade 0.004 0.050
Grade 1 1 1
Grade 2 2.503 (1.146–5.466) 3.040 (0.823–11.230)
Grade 3 3.324 (1.538–7.185) 3.467 (0.938–12.809)
Grade 4 4.434 (1.894–10.378) 6.702 (1.731–25.946)
Adjuvant chemotherapy 0.742 0.603
No 1 1
Yes 0.921 (0.562–1.507) 0.835 (0.423–1.648)
HR hazard ratio, CI confidence interval, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection,
LN lymph node, LVI lymphovascular invasion, PNI perineural invasion
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Subgroup analysis of the benefit of adjuvant chemotherapy
In general, AC was not associated with improved
DFS and OS in the entire sample (Additional file 1:
Table S1) or propensity score-matched patient cohort
(Additional file 1: Table S2). However, AC was
associated with poor DFS and OS among patients
older than 70 years in both study subsets.
Discussion
In this study, we evaluated the outcomes of LARC for
patients with ypT0-3N0, who are considered to have a
relatively good prognosis, after preoperative CRT
followed by TME, based on receipt of AC. AC did not
improve survival in these patients. Because the analysis
was conducted using data from a prospectively
collected tumor registry, the adjuvant group was
younger, had a more advanced pathologic stage, and
experienced a poor response to preoperative CRT,
compared with the observation group. Even after pro-
pensity score matching for these reasons, AC was also
not associated with improved outcomes in terms of
DFS and OS in the propensity score-matched cohort.
We were also not able to identify any specific subpop-
ulations that benefited from AC. These results were
comparable with those from previous studies regarding
the roles of AC in LARC after preoperative CRT or
radiotherapy [17–20].
Before the era of preoperative CRT and TME, AC was
associated with improved outcomes in rectal cancer
[10, 21]. As loco-regional recurrence rates have recently
decreased after the introduction of TME, reduction in
distant metastases has become more important in rectal
cancer treatment, similar to colon cancer. In addition,
substantial improvements have been achieved recently
Fig. 2 Kaplan-Meier survival plots of disease-free survival (a) and overall survival (b) based on the receipt of adjuvant chemotherapy in the entire sample
Fig. 3 Kaplan-Meier survival plots of disease-free survival (a) and overall survival (b) based on receipt of adjuvant chemotherapy in the propensity
score-matched cohort
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Table 3 Factors associated with disease-free survival and overall survival in the cohort of propensity score-matched patients with
ypT0-3N0 rectal cancer
Disease-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age, years 0.038 0.382 0.025 0.269
< 70 1 1 1 1
≥ 70 1.873 (1.036–3.386) 1.324 (0.706–2.483) 2.513 (1.125–5.609) 1.598 (0.695–3.673)
Sex 0.220 0.030 0.075
Female 1 1 1 1
Male 1.553 (0.769–3.138) 4.951 (1.167–21.005) 3.782 (0.875–16.352)
Distance from AV (cm) 0.511 0.416
≥ 10.0 1 1
5.0–9.9 0.669 (0.256–1.745) 0.510 (0.146–1.784)
< 5.0 0.956 (0.383–2.391) 0.897 (0.281–2.862)
Differentiation 0.896 0.464
Well 1 1
Moderate 0.842 (0.411–1.726) 0.579 (0.233–1.439)
Poor, mucinous 0.871 (0.271–2.803) 0.868 (0.220–3.432)
Pretreatment CEA (ng/mL) 0.014 0.039 0.348
< 5 1 1 1
≥ 5 2.075 (1.156–3.727) 1.912 (1.033–3.540) 1.461 (0.662–3.226)
Surgical procedure 0.039 0.339 0.033 0.225
LAR 1 1 1 1
APR 2.133 (1.038–4.384) 1.465 (0.670–3.206) 2.615 (1.082–6.319) 1.764 (0.705–4.411)
Stage 0.003 0.019 0.002 0.007
ypT0 1 1 1 1
ypT1 4.239 (1.299–13.831) 3.461 (1.017–11.778) 10.163 (2.033–50.817) 6.894 (1.343–35.381)
ypT2 2.388 (1.040–5.485) 1.893 (0.808–4.434) 2.243 (0.555–9.059) 1.647 (0.387–7.005)
ypT3 4.438 (1.963–10.032) 3.517 (1.528–8.093) 7.533 (2.114–26.848) 5.782 (1.588–21.051)
LN dissected 0.729 0.946
≥ 12 1 1
< 12 0.901 (0.500–1.624) 1.028 (0.467–2.259)
LVI/PNI 0.294 0.591
Negative 1 1
Positive 2.149 (0.516–8.955) 0.047 (0.000–3244.523)
Margin <0.001 0.001 <0.001 0.005
Negative 1 1 1 1
Positive 8.956 (3.131–25.613) 7.193 (2.234–23.156) 10.375 (3.022–35.623) 7.035 (1.806–27.404)
Mandard regression grade 0.006 0.039
Grade 1 1 1
Grade 2 3.086 (1.319–7.222) 5.268 (1.398–19.860)
Grade 3 4.542 (1.880–10.970) 4.113 (0.920–18.379)
Grade 4 3.771 (1.263–11.261) 8.159 (1.825–36.482)
Adjuvant chemotherapy 0.688 0.655
No 1 1
Yes 1.129 (0.626–2.035) 1.200 (0.539–2.669)
HR hazard ratio, CI confidence interval, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection,
LN lymph node, LVI lymphovascular invasion, PNI perineural invasion
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in the management of rectal cancer after the introduc-
tion of preoperative CRT and TME. However, the long-
term results of the EORTC 22921 [14], CHRONICLE
[22], I-CNR-RT [23], PROCTOR/SCRIPT [3], and
QUASAR trials [24] are controversial regarding the
benefits of AC in patients with LARC after preoperative
CRT or radiotherapy followed by surgery. Although the
rationale for AC after preoperative CRT was largely ex-
trapolated from the results obtained with colon cancer,
the clinical benefit of AC in rectal cancer needs to be
validated, considering the different treatment modal-
ities, recurrence patterns, and tumor biology [25, 26].
No conclusive evidence favoring AC in LARC after
preoperative CRT and TME currently exists [27].
For colon cancer, the benefit of AC has been clearly
demonstrated for patients with stage III disease in mul-
tiple clinical trials and meta-analyses [4–7]. However,
the benefit of AC in stage II colon cancers is less certain
[28, 29]. For patients with stage II T4 colon cancer, AC
was associated with improved survival [30]. Therefore,
we evaluated whether AC is needed in patients with
LARC with ypT0-3N0 after preoperative CRT as well as
the subgroup(s) that benefit from AC. However, AC did
not appear to benefit any specific subgroup.
There are several possible reasons for a lack of clinical
benefit from AC in patients with LARC and ypT0-3N0
after preoperative CRT and TME. First, AC is effective
for patients who have a poor prognosis, such as those
with stage III or T4 [30]. According to the ADORE trial,
which examined the role of oxaliplatin, fluorouracil, and
leucovorin as AC for LARC, survival was improved with
AC in patients with postoperative pathological stage III
disease but not in patients with stage II disease [15].
Second, there are embryological, anatomical, and physio-
logical differences between colon and rectal cancers.
Miscosatellite instability and BRAF mutation are import-
ant prognostic factors but are detected less often in
rectal cancer than in colon cancer. A meta-analysis by
Breugom et al. suggested that AC might benefit patients
with a tumor located 10–15 cm from the anal verge
[31], and theoretically, a tumor arising above the peri-
toneal reflection is more likely to undergo distant spread
[32]. Last, the lack of benefit with AC might be attrib-
uted to poor compliance. Only 42.9% of participants in
the EORTC 22921 trial [13], 43% of participants in the
CHRONICLE trial [22], and 55% of the participants who
received 3–6 courses of AC in the I-CNR-RT trial [23]
benefited from AC.
The researchers of the QUASAR trial identified the
patient subgroups that were more likely to benefit from
AC: <70 years old, receipt of chemotherapy every
4 weeks, and <6 weeks from surgery to AC [24]. How-
ever, we did not identify a subgroup that benefited from
AC in the current study, although old age was associated
with worse prognosis with AC. Therefore, routine use of
AC should be evaluated carefully, considering not only
the patient characteristics, such as age and comorbidi-
ties, but also tumor characteristics, such as distance
from the anal verge and the optimal chemotherapy
regimen and duration.
This study has certain limitations. First, the analysis
was based on data that were prospectively collected in a
tumor registry. Therefore, the baseline characteristics
differed, although we corrected this using propensity
score-matched analysis. In addition, immortal time bias,
caused by a period of time during which events cannot
occur [33], could act as a confounding factor. However,
we found no definite differences in early recurrence or
death as well as DFS and OS at different cut-off times
after surgery between the adjuvant and observation
groups in this study (Additional file 1: Tables S3 and S4).
Also, this bias has clearly not affected the conclusion,
because immortal time bias would tend to favor the ad-
juvant chemotherapy arm if present. Second, this study
was conducted with a relatively small sample size, thus
underpowered to ascertain the effect of adjuvant chemo-
therapy. However, the effect size found in the cohort of
propensity-matched patients was 1.129 (HF for DFS),
which is the opposite direction of the benefit from adju-
vant chemotherapy as well as seems to be clinically
irrelevant. Furthermore, statistical power for detecting
such HR is less than 10%, which means that a huge
sample size is needed to show statistical significance.
Third, the results were derived from a single tertiary
center, potentially lacking the external validation.
Conclusions
In summary, LARC patients with ypT0-3N0 did not
benefit from AC after preoperative CRT and TME,
which supports the findings of previous studies investi-
gating the role of AC after preoperative CRT and TME
and the conclusions of meta-analyses. However, there
are conflicting results about the use of AC from many
studies with diverse patient populations. Based on this
context, a more intensive investigation is needed to
evaluate the potential advantages and drawbacks of AC
in the era of preoperative CRT and TME. Moreover,
future studies should focus on identifying patient
subpopulations that benefit from AC.
Additional file
Additional file 1: Table S1. Effect of adjuvant chemotherapy on
disease-free survival and overall survival by patient demographics and
tumor characteristics in the entire sample of patients. Table S2. Effect of
adjuvant chemotherapy on disease-free survival and overall survival by
patient demographics and tumor characteristics in the cohort of propensity
score-matched patients. Table S3. Recurrence or death events at different
times after surgery. Comparisons were done by Fisher’s exact test.
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Table S4. Effect of adjuvant chemotherapy on disease-free survival and
overall survival by restricting analysis to patients who remained event-free at
different times after surgery. (DOCX 30 kb)
Abbreviations
5-FU: 5-fluorouracil; AC: Adjuvant chemotherapy; AJCC: American Joint
Committee on Cancer; CEA: Carcinoembryonic antigen; CI: Confidence
interval; CRT: Chemoradiation therapy; CT: Computed tomography;
DFS: Disease-free survival; HR: Hazard ratio; IQR: Interquartile range;
LARC: Locally advanced rectal cancer; OS: Overall survival; PET: Positron
emission tomography; TME: Total mesorectal excision
Acknowledgements
The authors thank Dong-Su Jang for graphical assistance (Medical Research
Support section, Yonsei University College of Medicine, Seoul, Korea), and Su
Kyoung Park for data management assistance (Analysis Division of Medical
Record Team, Yonsei Cancer Center, Seoul, Korea).
Funding
This work was supported in part by a grant from the National R&D Program
for Cancer Control, Ministry of Health and Welfare, Republic of Korea
(1420270) and National Research Foundation, Ministry of Science, ICT and
Future Planning, Republic of Korea (2015R1C1A1A01053547), which provided
financial support for writing and editing the manuscript. The funding bodies
were not involved in design of the study, collection, analysis, and
interpretation of the data.
Availability of data and materials
The dataset supporting the conclusions of this article is available upon
request from the corresponding author.
Authors’ contributions
CGK, JBA, SJS, SHB, CK, IJ, MJ have made substantial contributions to the
conception and design of this study. SJH, HSP, JHK, EAC, WSK, HH, BSM, NKK, HK
carried out analysis and interpretation of data. CGK, IJ, MJ have been involved in
drafting the manuscript. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the institutional review board of Yonsei Cancer
Center, Seoul, Korea. Written informed consent was obtained before
treatment from patients.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Medical Oncology, Department of Internal Medicine, Yonsei
Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea.
2Graduate School of Medical Science and Engineering, KAIST, Daejeon, South
Korea. 3Department of Radiation Oncology, Yonsei Cancer Center, Seoul,
South Korea. 4Department of Surgery, Yonsei Cancer Center, Seoul, South
Korea. 5Department of Pathology, Yonsei Cancer Center, Seoul, South Korea.
6Division of Medical Oncology, Department of Internal Medicine, CHA
Bundang Medical Center, Seongnam, South Korea. 7Department of
Biostatistics and Medical Informatics, Yonsei University College of Medicine, 50-1
Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea.
Received: 14 January 2017 Accepted: 28 August 2017
References
1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision
for rectal cancer. Lancet. 1986;1:1479–82.
2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N
Engl J Med. 2004;351:1731–40.
3. Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB,
Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated
with preoperative (chemo)radiotherapy and total mesorectal excision: a
Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann
Oncol. 2015;26:696–701.
4. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al.
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as
adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin
Oncol. 2009;27:3109–16.
5. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et
al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as
surgical adjuvant chemotherapy for stage II and III colon cancer: results
from NSABP C-07. J Clin Oncol. 2007;25:2198–204.
6. Shah MA, Renfro LA, Allegra CJ, Andre T, de Gramont A, Schmoll HJ, et al.
Impact of patient factors on recurrence risk and time dependency of
oxaliplatin benefit in patients with colon cancer: analysis from modern-era
adjuvant studies in the adjuvant colon cancer end points (ACCENT)
database. J Clin Oncol. 2016;34:843–53.
7. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al.
Evidence for cure by adjuvant therapy in colon cancer: observations based
on individual patient data from 20,898 patients on 18 randomized trials. J
Clin Oncol. 2009;27:872–7.
8. Kim NK, Hur H. New perspectives on predictive biomarkers of tumor
response and their clinical application in preoperative chemoradiation
therapy for rectal cancer. Yonsei Med J. 2015;56:1461–77.
9. Huh JW, Lee WY, Kim SH, Park YA, Cho YB, Yun SH, et al.
Immunohistochemical detection of p53 expression in patients with
preoperative chemoradiation for rectal cancer: association with prognosis.
Yonsei Med J. 2015;56:82–8.
10. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S.
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Cochrane Database Syst Rev. 2012. doi:10.1002/14651858.CD004078.pub2:
Cd004078.
11. Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;
24(Suppl 6):vi81–8.
12. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A,
Blomqvist L, et al. EURECCA colorectal: multidisciplinary management:
European consensus conference colon & rectum. Eur J Cancer. 2014;50:1
e1–1 e34.
13. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al.
Patients with curative resection of cT3-4 rectal cancer after preoperative
radiotherapy or radiochemotherapy: does anybody benefit from adjuvant
fluorouracil-based chemotherapy? A trial of the European Organisation for
Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol.
2007;25:4379–86.
14. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ,
et al. Fluorouracil-based adjuvant chemotherapy after preoperative
chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921
randomised study. Lancet Oncol. 2014;15:184–90.
15. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin,
fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant
chemotherapy for locally advanced rectal cancer after preoperative
chemoradiotherapy (ADORE): an open-label, multicentre, phase 2,
randomised controlled trial. Lancet Oncol. 2014;15:1245–53.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th
edition of the AJCC cancer staging manual and the future of TNM. Ann
Surg Oncol. 2010;17:1471–4.
17. Kiran RP, Kirat HT, Burgess AN, Nisar PJ, Kalady MF, Lavery IC. Is adjuvant
chemotherapy really needed after curative surgery for rectal cancer patients
who are node-negative after neoadjuvant chemoradiotherapy? Ann Surg
Oncol. 2012;19:1206–12.
18. Huh JW, Kim HR. Postoperative chemotherapy after neoadjuvant
chemoradiation and surgery for rectal cancer: is it essential for patients with
ypT0-2N0? J Surg Oncol. 2009;100:387–91.
19. Jung KU, Kim HC, Park JO, Park YS, Park HC, Choi DH, et al. Adjuvant
chemotherapy after neoadjuvant chemoradiation and curative resection for
rectal cancer: is it necessary for all patients? J Surg Oncol. 2015;111:439–44.
Kim et al. BMC Cancer  (2017) 17:615 Page 9 of 10
20. Park IJ, Kim DY, Kim HC, Kim NK, Kim HR, Kang SB, et al. Role of adjuvant
chemotherapy in ypT0-2N0 patients treated with preoperative
chemoradiation therapy and radical resection for rectal cancer. Int J Radiat
Oncol Biol Phys. 2015;92:540–7.
21. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et
al. Postoperative adjuvant chemotherapy or radiation therapy for rectal
cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21–9.
22. Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows
HM, et al. Chronicle: results of a randomised phase III trial in locally
advanced rectal cancer after neoadjuvant chemoradiation randomising
postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Ann Oncol. 2014;25:1356–62.
23. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER,
Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin
chemotherapy after neoadjuvant chemoradiotherapy in locally advanced
cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-
RT). Radiother Oncol. 2014;113:223–9.
24. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant
chemotherapy versus observation in patients with colorectal cancer: a
randomised study. Lancet. 2007;370:2020–9.
25. Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, et al.
Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001;
195:171–8.
26. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P,
Aaltonen LA, et al. Differential gene expression in colon cancer of the
caecum versus the sigmoid and rectosigmoid. Gut. 2005;54:374–84.
27. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based
chemotherapy provide a benefit for patients with resected rectal cancer
who have already received neoadjuvant radiochemotherapy? A systematic
review of randomised trials. Ann Oncol. 2010;21:1743–50.
28. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et
al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for
stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13:2936–43.
29. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R,
Tschmelitsch J, et al. A prospective randomised phase III trial of adjuvant
chemotherapy with 5-fluorouracil and leucovorin in patients with stage II
colon cancer. Br J Cancer. 2007;97:1021–7.
30. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant
chemotherapy use and outcomes of patients with high-risk versus low-risk
stage II colon cancer. Cancer. 2015;121:527–34.
31. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al.
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and
surgery for patients with rectal cancer: a systematic review and meta-
analysis of individual patient data. Lancet Oncol. 2015;16:200–7.
32. Benzoni E, Terrosu G, Bresadola V, Cerato F, Cojutti A, Milan E, et al. Analysis
of clinical outcomes and prognostic factors of neoadjuvant
chemoradiotherapy combined with surgery: intraperitoneal versus
extraperitoneal rectal cancer. Eur J Cancer Care (Engl). 2006;15:286–92.
33. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol.
2008;167:492–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. BMC Cancer  (2017) 17:615 Page 10 of 10
